Triple-negative breast cancer (TNBC) remains a challenging disease to treat due to its heterogeneity and poor prognosis compared to hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-positive breast cancers [1]. This evidence concerns the gene ERBB2 and breast cancer.